Aprea Therapeutics (APRE) Competitors $1.69 -0.02 (-1.17%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.72%) As of 08/14/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. OVID, RANI, ENLV, KPTI, XLO, MRSN, MDCX, CLSD, SNYR, and AKTXShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Ovid Therapeutics (OVID), Rani Therapeutics (RANI), Enlivex Therapeutics (ENLV), Karyopharm Therapeutics (KPTI), Xilio Therapeutics (XLO), Mersana Therapeutics (MRSN), Medicus Pharma (MDCX), Clearside Biomedical (CLSD), Synergy CHC (SNYR), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors Ovid Therapeutics Rani Therapeutics Enlivex Therapeutics Karyopharm Therapeutics Xilio Therapeutics Mersana Therapeutics Medicus Pharma Clearside Biomedical Synergy CHC Akari Therapeutics Ovid Therapeutics (NASDAQ:OVID) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Is OVID or APRE more profitable? Ovid Therapeutics has a net margin of -574.44% compared to Aprea Therapeutics' net margin of -1,645.01%. Ovid Therapeutics' return on equity of -56.24% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-574.44% -56.24% -41.46% Aprea Therapeutics -1,645.01%-78.90%-62.67% Do insiders and institutionals believe in OVID or APRE? 72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, OVID or APRE? Aprea Therapeutics has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$570K104.83-$26.43M-$0.35-2.40Aprea Therapeutics$1.50M6.57-$12.96M-$2.32-0.73 Do analysts rate OVID or APRE? Ovid Therapeutics presently has a consensus price target of $3.10, indicating a potential upside of 268.92%. Aprea Therapeutics has a consensus price target of $15.50, indicating a potential upside of 817.16%. Given Aprea Therapeutics' higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Ovid Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OVID or APRE? In the previous week, Ovid Therapeutics had 8 more articles in the media than Aprea Therapeutics. MarketBeat recorded 14 mentions for Ovid Therapeutics and 6 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.95 beat Ovid Therapeutics' score of 0.50 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, OVID or APRE? Ovid Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. SummaryOvid Therapeutics beats Aprea Therapeutics on 10 of the 17 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.96M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.7320.4930.2925.74Price / Sales6.57356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book0.738.608.826.15Net Income-$12.96M-$54.65M$3.25B$265.06M7 Day Performance-0.59%5.86%3.70%2.60%1 Month Performance3.68%8.86%5.84%2.83%1 Year Performance-50.44%13.33%29.92%25.58% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics3.5949 of 5 stars$1.69-1.2%$15.50+817.2%-48.0%$9.96M$1.50M-0.737Earnings ReportOVIDOvid Therapeutics4.4243 of 5 stars$0.50+1.3%$3.13+521.3%-16.8%$35.84M$570K-1.4460Trending NewsEarnings ReportShort Interest ↑Gap DownRANIRani Therapeutics3.4968 of 5 stars$0.56+1.8%$7.33+1,214.2%-79.1%$35.33M$1.20M-0.56110Short Interest ↓ENLVEnlivex Therapeutics3.3385 of 5 stars$1.49+0.7%$10.00+571.1%+42.4%$35.24MN/A-2.2670News CoverageShort Interest ↓KPTIKaryopharm Therapeutics3.6495 of 5 stars$3.99-0.9%$37.40+838.5%-61.6%$34.43M$145.24M-0.30380Earnings ReportAnalyst ForecastAnalyst RevisionXLOXilio Therapeutics2.8356 of 5 stars$0.66+0.1%$4.00+507.9%-14.8%$34.07M$6.34M-0.7870News CoverageEarnings ReportMRSNMersana Therapeutics4.0981 of 5 stars$6.77-1.4%$130.00+1,821.4%-75.9%$33.83M$40.50M-0.46150Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓MDCXMedicus Pharma2.1365 of 5 stars$2.38flat$23.50+887.4%N/A$32.30MN/A-2.05N/AEarnings ReportAnalyst ForecastCLSDClearside Biomedical2.7916 of 5 stars$0.41-0.3%$4.20+914.5%-56.0%$32.09M$1.66M-1.0130Earnings ReportShort Interest ↑Gap UpSNYRSynergy CHC4.0858 of 5 stars$3.49-0.6%$10.00+186.5%N/A$32.07M$34.83M0.0040News CoverageEarnings ReportAKTXAkari Therapeutics3.0984 of 5 stars$1.00-3.4%$5.00+402.5%-69.5%$31.99MN/A0.009Upcoming Earnings Related Companies and Tools Related Companies OVID Competitors RANI Competitors ENLV Competitors KPTI Competitors XLO Competitors MRSN Competitors MDCX Competitors CLSD Competitors SNYR Competitors AKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access